Advancing Vaccine Technologies Is Anticipated To Openup The New Avanue For IPV Vaccines Market
![]() |
| IPV Vaccines Market |
The IPV Vaccines Market is estimated to be valued at US$ 188.36 Mn or Million in 2023 and is expected to exhibit a CAGR of 8.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
IPV or Inactivated Polio Vaccine is a vaccine used around the world to prevent
poliomyelitis (polio). The vaccine contains killed (inactivated) poliovirus
that cannot cause polio. When a person is vaccinated with IPV, their body
recognises the virus as foreign and makes antibodies against it. If the person
later comes into contact with "wild" or live poliovirus, their body
is prepared to fight it off and prevent infection. IPV mainly helps develop
herd immunity in the community by stopping transmission of the virus. It is
given as injections and requires multiple doses for full protection. IPV
vaccines are produced by various leading manufacturers globally and
administered as part of routine immunisation programs.
Market Dynamics:
The global IPV vaccines market is primarily driven by growing immunization
programs by governments and health organizations to eradicate polio disease
globally. According to WHO, as long as a single child remains infected with
poliovirus, children in all countries are at risk of contracting the disease.
To achieve a polio-free world, over 95% of children must be fully immunized so
that the virus does not have the opportunity to spread and can potentially be
eradicated globally. This has resulted in increased adoption of IPV vaccines
worldwide. Additionally, the WHO and Global Polio Eradication Initiative's
strategic push to switch from oral polio vaccine (OPV) to IPV in routine and
supplemental immunisation activities in order to stop the circulation of
vaccine-derived polioviruses (VDPVs) is positively impacting the market growth.
With IPV being the only option available that does not carry the risk of
vaccine-derived polio outbreaks post mass immunisation programs, the demand for
IPV vaccines is likely to increase significantly over the forecast period.

Comments
Post a Comment